Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and machine learning to develop targeted cancer therapies, announced that its management will present at the ThinkEquity Conference on October 15, 2026, at 3:30 p.m. ET. The event will take place at the Mandarin Oriental in New York City. A live webcast of the presentation will be available, and Lantern Pharma management will also be available for one-on-one investor meetings throughout the conference.
The presentation comes as Lantern Pharma continues to advance its proprietary RADR® AI and machine-learning platform, which integrates large-scale genomic and biological data to transform the cost, pace, and precision of oncology drug development. RADR is designed to identify patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
For investors and industry observers, the ThinkEquity Conference offers a direct window into Lantern Pharma's strategic direction and near-term milestones. Management's participation in one-on-one meetings signals a willingness to engage with the investment community, potentially increasing transparency around clinical timelines and data readouts. As AI-driven drug development gains traction, Lantern's progress could influence broader adoption of machine learning in oncology, where precision and speed are critical. The live webcast also extends access to a wider audience, allowing stakeholders unable to attend in person to follow the presentation in real time.
To view the full press release, visit https://ibn.fm/hmTGq. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
The announcement was distributed via InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication for private and public companies and the investment community. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers. InvestorWire also offers a full array of tailored corporate communications solutions. Terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.
